Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor  by Yeung, Sai F. et al.
1292 Journal of Thoracic Oncology ®  •  Volume 10, Number 9, September 2015
Introduction: Oncogenic driver mutations activating receptor tyro-
sine kinase pathways are promising predictive markers for targeted 
treatment. We investigated the mutation profile of an updated driver 
events list on receptor tyrosine kinase/RAS/PI3K axis and the clini-
copathologic implications in a cohort of never-smoker predominated 
Chinese lung adenocarcinoma.
Methods: We tested 154 lung adenocarcinomas and adenosquamous 
carcinomas for EGFR, KRAS, HER2, BRAF, PIK3CA, MET, NRAS, 
MAP2K1, and RIT1 mutations by polymerase chain reaction-direct 
sequencing. MET amplification and ALK and ROS1 translocations 
were assessed by fluorescent in situ hybridizations. MET and thy-
roid transcription factor-1 protein expressions were investigated by 
immunohistochemistry.
Results: Seventy percent of lung adenocarcinomas carried action-
able driver events. Alterations on EGFR (43%), KRAS (11.4%), 
ALK (6%), and MET (5.4%) were frequently found. ROS1 trans-
location and mutations involving BRAF, HER2, NRAS, and 
PIK3CA were also detected. No mutation was observed in RIT1 and 
MAP2K1. Patients with EGFR mutations had a favorable progno-
sis, whereas those with MET mutations had poorer overall survival. 
Multivariate analysis further demonstrated that MET mutation was 
an independent prognostic factor. Although MET protein expres-
sion was detected in 65% of lung adenocarcinoma, only 10% of 
the MET-immunohistochemistry positive tumors harbor MET DNA 
alterations that drove protein overexpression. Appropriate predictive 
biomarker is essential for selecting patients who might benefit from 
specific targeted therapy.
Conclusion: Actionable driver events can be detected in two thirds 
of lung adenocarcinoma. MET DNA alterations define a subset 
of patients with aggressive diseases that might potentially benefit 
from anti-MET targeted therapy. High negative predictive values of 
thyroid transcription factor-1 and MET expression suggest poten-
tial roles as surrogate markers for EGFR and/or MET mutations.
Key Words: Lung cancer, EGFR, KRAS, ALK, HER2, BRAF, MET, 
ROS1, RIT1, TTF-1 lung adenocarcinoma, NRAS, Driver mutations, 
Oncogenic driver mutation, East Asian lung cancer, MET amplifica-
tion, Targeted therapy, Genetic marker, Biomarker, Molecular clas-
sification lung cancer.
(J Thorac Oncol. 2015;10: 1292–1300)
Lung cancer is the leading cause of cancer-related death worldwide.1 Over 98% of the lung cancers are carcinomas, 
including small-cell carcinoma and non–small-cell carcinoma 
(NSCLC). NSCLC is further classified into adenocarcinoma, 
squamous cell carcinoma, and large-cell carcinoma according 
to the pathological characteristics. Driver mutations activating 
the receptor tyrosine kinase (RTK) pathway have been found in 
more than 70% of the lung adenocarcinomas that can predict 
benefit from targeted therapies. Clinically, targeted agents against 
EGFR, ALK,2–6 RET,7 and ROS18,9 have dramatically improved 
the treatment outcome in patients with specific driver muta-
tions. Other targeting therapies against BRAF,10–12 ERBB2,13–16 
and PIK3CA are under investigations. Efforts in next generation 
sequencing studies have revealed rarer driver mutations includ-
ing NRG1,17,18 NTRK,19 ERBB4,18 BRAF18 fusion and MET,20–22 
ARAF,23 CRAF,23 RIT1,22,24 HRAS,25,26 and NRAS27,28 mutations 
that may serve as potential therapeutic targets. The number of 
predictive biomarkers with their matched targeted drugs enter-
ing clinical trials is expected to increase dramatically. This study 
aimed to comprehensively investigate the mutational profile 
of an updated list of diver genes on RTK/RAS/PI3K axis in a 
cohort of lung adenocarcinoma from Chinese ethnicity.
MATERIALS AND METHODS
Clinical Samples
The study cohort was a retrospective cohort retrieved 
from the pathology archive. It recruited patients with (1) lung 
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cancer undergoing surgical resection from December 1998 to 
December 2010 at Prince of Wales Hospital, Hong Kong, (2) 
histological diagnosis of adenocarcinoma or adenosquamous 
carcinoma, and (3) availability of frozen tissue. Specimens 
were collected with informed consent from the patients. The 
study protocol was approved by the Joint CUHK-NTE Clinical 
Research Ethics Committee, Hong Kong. All specimens were 
reviewed by a pathologist (K.F.T.) to confirm the histological 
diagnosis and tumor cell content. Patients’ demographic data 
and clinicopathological characteristics were obtained from 
medical records. The disease stage was determined according to 
the 7th edition of American Joint Committee on Cancer TNM 
classification system. The smoking status was either categorized 
into never-smoker (individuals smoke less than 100 cigarettes 
in their life-time) or ever-smoker (individuals smoke more 
than 100 cigarettes in their life-time).22 Patients with history 
of chemotherapy before surgery, demographic data missing, or 
nonprimary tumor were excluded. After surgical resection, all 
patients were followed up according to institutional practice. 
The duration of follow-up was calculated from the date of surgi-
cal operation to the date of the last follow-up (cut-off at June 30, 
2014) or death. Disease-specific overall survival was defined 
from the time of surgery to the time of cancer-related death. 
Relapse-free survival was defined from the time of curative sur-
gery to the time of radiological evidence of tumor relapse.
Microdissection and DNA Extraction
DNA was extracted from both frozen and formalin-fixed 
paraffin-embedded tumor tissues using QIAamp DNA mini 
kit (QIANGEN, Valencia, CA) according to the manufac-
turer’s instruction. Manual microdissection was performed to 
ensure more than 50% tumor content in each DNA sample for 
subsequent analysis.
Mutational Analysis
EGFR exon 18–21, KRAS exon 2 and 3, HER2 exon 20, 
BRAF codon 600 and 601, MET exon 14 and intron boundar-
ies, MAP2K1 exon 2, PIK3CA exon 9 and 20, NRAS exon 2 
and RIT1 exon 4 and 5 were screened by polymerase chain 
reaction (PCR) and direct sequencing. PCR primer sequences, 
annealing temperatures, and cycling conditions were listed 
in Supplementary Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A853). The PCR products were 
purified and sequenced using the BigDye Terminator Cycle 
Sequencing Ready Reaction kit (Applied Biosystems, Foster 
city, CA) and analyzed by the Life Technologies 3130xl 
Genetic Analyzer. The data were collected and analyzed using 
Applied Biosystems sequencing analysis software. The DNA 
sequence was compared with consensus coding sequences 
from the Consensus Coding DNA Sequnce Database.
Construction of Tissue Microarray
Tissue microarrays were constructed using a tis-
sue arrayer (Beecher Instruments, Silver Spring, MD). The 
location of tumor area on the donor formalin-fixed paraffin-
embedded tissue block was first marked on the hematoxylin 
and eosin-stained histological section. Three representative 
1-mm cores were obtained from each tumor and inserted to a 
recipient paraffin block. For fluorescent in situ hybridization 
(FISH) and immunohistochemistry (IHC), 4-μm tissue sec-
tions were prepared and mounted onto Superfrost Plus micro-
scope slides.
Fluorescent In Situ Hybridization
ALK and ROS1 translocation status were investigated by 
using commercial break apart FISH probes: Vysis LSI ALK Dual 
Color Break Apart Rearrangement Probe (Abbott Molecular, 
Abbott Park, IL) and Aquarius ROS1 Break Apart probe 
(Cytocell, Cambridge, GB). At least 100 informative tumor nuclei 
were examined. Only nuclei showing both green and red signals 
were considered informative. Positive ALK or ROS1 rearrange-
ments were defined as more than 15% of the tumor cells carried 
break apart signals. MET gene copy number/amplification status 
was investigated by MET/CEP7 FISH probe (Abbott Molecular, 
IL). Copy number per cell and MET/CEP7 ratio were counted in 
at least 50 nonoverlapping tumor cell nuclei. MET amplification 
was defined by MET/CEP7 ratio greater than or equal to 2.
Immunohistochemistry
IHC was carried out using Benchmark XT autostainer 
(Ventana, Tucson, AZ) using Ultraview detection system. MET 
IHC was performed using Confirm anti-total c-MET (SP44) 
rabbit monoclonal antibody (Ventana, Tucson, AZ) accord-
ing to manufacturer’s instruction. Expression level of MET 
protein was determined by a scoring system considering both 
staining intensity and prevalence of intensities in tumor cells. 
The four staining score were defined as following: 3+ (≥50% 
of tumor cells staining with strong intensity); 2+ (≥50% of 
tumor cells with moderate or higher staining but <50% with 
strong intensity); 1+ (≥50% of tumor cells with weak or higher 
staining but <50% with moderate or higher intensity); or 0 (no 
staining or <50% of tumor cells with any intensity).29 Tumors 
with moderate to strong MET protein expression (scores 2+ 
and 3+) were considered positive, whereas scores 0 and 1+ 
were regarded as negative for MET expression.
For thyroid transcription factor-1 (TTF-1) staining, 
antigen retrieval was performed at boiling point in 1 mM eth-
ylenediaminetetraacetic acid (pH 8.0). The slides were incu-
bated with the primary monoclonal antibodies against TTF-1, 
clones 8G7G3/1 (dilution 1:75; Dako, Glostrup, Denmark) for 
32 minutes at 37°C. All slides were counterstained with hema-
toxylin. Positive nuclear staining was defined as moderate to 
strong staining in the nuclei of any of the tumor cells
Statistical Analysis
Statistical analysis was performed using SPSS 19.0 
(IBM Corp., Armonk, NY). Chi-square and Fisher’s exact 
test were used to analyze associations of mutational, protein 
expression and gene copy number status with clinical char-
acteristics. The Kaplan–Meier method was used to estimate 
the survival rates for different groups. The equivalences of 
the survival curves were tested by log-rank statistics. The 
Cox proportional hazards model was employed for univariate 
and multivariate survival analyses. Those variables being sta-
tistically significant found in the univariate survival analysis 
were further evaluated in the multivariate survival analysis. 
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A two-tailed p value of less than 0.05 was considered to be 
statistically significant.
RESULTS
Patient Characteristics
Frozen tumor tissues were available from a total of 166 
patients who underwent surgery for lung cancer in the stud-
ied period. Among them 12 patients were excluded because 
of nonadenocarcinoma/adenosquamous carcinoma (n = 8), 
incomplete clinicopathological data (n = 3), and non-lung 
primary tumor (n = 1). The remaining 154 patients included 
149 with lung adenocarcinoma and 5 with adenosquamous 
carcinoma. Eighty-six (55.8%) were male, and 68 (44.2%) 
were female. The mean age was 64.3 years (range 28–90 
years). Among 149 patients with adenocarcinoma, most of the 
female subjects (80.6%) were never-smoker, whereas majority 
of the male subjects (63.4%) were ever-smokers (p < 0.001). 
According to the 7th edition of American Joint Committee on 
Cancer TNM staging, 69 patients (46.3%) were classified as 
stage I, 27 patients (18.1%) as stage II, 36 patients (24.2%) 
as stage III, and 17 patients (11.4%) as stage IV. For those 
patients underwent curative surgery (n = 132), resections were 
complete with margin clearance of more than 1 cm. Clinical 
characteristics of 149 patients with adenocarcinoma are dis-
played in Table 1. Details of the five patients with adeno-
squamous carcinoma were listed in Supplementary Table 2 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A853).
Mutation Spectrum in Lung Adenocarcinoma
Among 149 lung adenocarcinoma, 102 (68.5%) carried 
one driver mutation and two (1.3%) carried double mutations. 
A total of 106 driver mutations from 104 lung adenocarcino-
mas were identified. The remaining 45 (30.2%) tumors were 
found to be wild type from the genes we screened. The distri-
bution of driver mutations is shown in Figure 1.
EGFR and KRAS were found to be frequently mutated 
in lung adenocarcinoma, and their mutations were mutually 
exclusive with each other. EGFR mutation was detected in 
43% (64 of 149) of the adenocarcinomas. It was the most fre-
quently mutated gene in this cohort. Exon 19 deletions (34 
of 64, 53.1%) and exon 21 L858R point mutation (25 of 64, 
39.1%) accounted for 92.2% of all detected EGFR mutations. 
Other EGFR mutations included E709_T710delinsD (n = 1) 
and E709A (n = 1) on exon 18, L747P (n = 1) on exon 19, 
H773Q (n = 1) on exon 20, and L861Q (n = 1) on exon 21. 
No EGFR exon 20 insertion was detected in this study. KRAS 
mutation was detected in 11.4% (17 of 149) of the adenocarci-
nomas. G12 residue was found to be affected in 16 cases, and 
Q61 residue was found to be affected in one case.
ALK translocation was also usually detected (9 of 149, 
6%), as were MET exon 14 splice site mutations (6 of 149, 
4%), ROS1 translocation (3 of 149, 2%), MET amplification 
(2 of 149, 1.3%), and BRAF V600E mutation (2 of 149, 1.3%). 
Other driver mutations in HER2 (1 of 149, 0.7%), NRAS (1 of 
149, 0.7%), and PIK3CA (1 of 149, 0.7%) were observed. No 
mutation was detected in RIT1 and MAP2K1. Co-mutation 
was found in two tumors, one with NRAS (Q61H) and ALK 
translocation and the other with BRAF (V600E) and PIK3CA 
(E542K).
MET exon 14 splice site mutation was detected in six 
tumors. Two involved the deletion of the 5′ conserved polypy-
rimidine tract and the other four affected the 3′ splice-donor 
sites in intron 14. All these mutations were predicted to result 
in exon 14 skipping in MET mRNA (Fig. 2A). MET DNA 
amplification (MET/CEP7 ≥ 2) was found in two tumors 
(2 of 149, 1.3%, Fig. 2B). MET exon 14 splice site mutation 
and amplification were considered as oncogenic drivers that 
occurred mutually exclusively with other driver events of 
RTK/RAS/PI3K axis. Another five tumors were considered 
to have MET DNA copy number gain, which was defined by 
greater than or equal to five copies of MET DNA per cell. 
All five tumors with MET DNA copy number gain harbored 
co-mutations: two with coexisting MET exon 14 splice site 
mutations, one with KRAS mutation, and two with EGFR 
mutations.
MET IHC was successfully performed in 132 cases. 
Moderate to strong MET expression was found in 86 (65.1%) 
TABLE 1.  Clinicopathological Characteristics in Lung Adenocarcinoma
Parameter Female (%) Male (%) Total
Age (yr) Mean (SD) 63.4 (11.3) 64.8 (12.1) —
Range 34–82 28–90 —
Smoking status NS 54 (69.2) 24 (30.8) 78
ES 4 (7.1) 52 (92.9) 56
NA 9 (60.0) 6 (40.0) 15
Pathological stage I 29 (42.0) 40 (68.0) 69
II 11 (40.7) 16 (59.3) 27
III 21 (58.3) 15 (41.7) 36
IV 6 (35.3) 11 (64.1) 17
Tumor size (cm) Mean (SD) 3.1 (1.4) 3.75 (1.9) —
Range 1.0–8.0 1.5–10.0 -
Total 67 (45.0%) 82 (55.0%) 149
ES, ever smoker; NA, not available; NS, never smoker; SD, standard derivation.
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tumors, whereas 46 (34.9%) cases were scored negative 
(Fig. 2C). All tumors with MET DNA alterations, including 
MET exon 14 splice site mutations, MET DNA amplification, 
and MET copy number gain were positive for MET protein 
expression. In 46 tumors that were negative for MET protein 
expression, no DNA alteration of MET gene was detected. 
Therefore, MET IHC had a 100% sensitivity (95% confi-
dence interval [CI]: 71.3–100%) and negative predictive value 
EGFR, 43.0%
KRAS, 11.4%
ALK, 6.0%
MET mut, 4.0%
ROS1, 2.0%
MET amp, 1.3%
BRAF, 1.3%
HER2, 0.7%
NRAS, 0.7%
PIK3CA, 0.7%
WT, 30.2%
EGFR
KRAS
ALK
MET mut
ROS1
MET amp
BRAF
HER2
NRAS
PIK3CA
WT
A
B
C
FIGURE 1. A, Frequencies of known oncogenic drivers on RTK/RAS/PI3K axis in lung adenocarcinoma (n = 149). Co-mutation 
plot for oncogenic driver stratified according to (B) gender and (C) smoking status.
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(95% CI: 92.2–100%), though the specificity was 38% (95% 
CI: 29.4–47.3%) only, and the positive predictive value was 
12.8% (95% CI: 6.6–21.8%).
Mutation Status in Lung 
Adenosquamous Carcinoma
Five cases of adenosquamous carcinoma were included in 
this study. Driver mutation was detected in two tumors, includ-
ing one with EGFR exon 19 deletion and one with ALK trans-
location. Both patients were never smokers. No mutation was 
identified in the other three cases (Table 3, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A853).
Correlation Between Driver Mutations 
and Clinicopathological Features
EGFR mutation rate was significantly higher in never-
smokers than ever-smokers (59% versus 25%, p < 0.001), and 
in patients without lymph node metastasis (p = 0.034). There 
was a trend toward higher EGFR mutation rate in female than 
male (50.7% versus 36.6%, p = 0.082), although it was not 
statistically significant. No association was found between 
EGFR mutation status with patient’s age, tumor size, and the 
pathological stages. On the contrary, KRAS mutations rate 
was significantly higher in ever-smokers than in never-smok-
ers (p = 0.016) and in male patients (p = 0.003). ALK trans-
location was associated with younger age (52.7 versus 64.9 
years, p = 0.01) and smaller tumor size (p = 0.015). Patients 
with MET exon 14 splice site mutations were significantly 
older (78.7 versus 63.6 years, p = 0.001), and the mutation 
status was correlated with MET DNA copy number gain (copy 
number ≥ 5, p = 0.016). Correlations of genotype with clinico-
pathological characteristics are listed in Table 2.
TTF-1 is a lineage specific maker that is uniformly 
expressed in the terminal respiratory unit (TRU) composed of 
peripheral airway cells and small-sized bronchioles. Given its 
role in lineage specification of lung epithelium, TTF-1 has been 
used as biomarker for primary lung adenocarcinoma. TTF-1 
IHC was successfully performed in 138 cases. The results 
showed that 130 tumors (94.2%) were TTF-1 positive. The 
presence of TTF-1 expression positively correlated with EGFR 
mutation (p = 0.021) and negatively correlated with KRAS 
Diploid
Polyploid
2X Amp
Cluster Amp
A PyPyPy….PyPy AG exon 14 GT
-29 -24 -9
Intron 13 Intron 14
Polypyrimidine TractBranch Point 3’ splice site 5’ splice site
c. 2941 c. 3082
c. 3082+delG 
c. 3082+3_A>T
c. 3082G>C
c. 3082G>T c.2941-23_2941-10del13
c.2941-8_2967del36
A
B
C
FIGURE 2.  MET alterations in lung adeno-
carcinoma. A, Schematic illustration of the 
location of MET exon 14 splice site muta-
tions found in this study. B, Representative 
images of MET FISH analysis. C, 
Representative images showing negative, 
moderate, and strong MET protein expres-
sion by immunohistochemistry.
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mutation (p = 0.007). Moreover, all TTF-1 negative tumors 
were negative for EGFR and MET mutations. Thus, the nega-
tive predictive values of TTF-1 for EGFR and MET mutations 
are 100% (95% CI: 62.9–100%). The finding suggested that 
TTF-1 might serve as a negative predictor for EGFR and MET 
mutations in lung adenocarcinomas (Table 3).
Survival Analysis
The follow-up data were available in 138 patients. The 
median follow-up time was 34.5 months. At the time of evalu-
ation, 79 patients (57.2%) were still alive, whereas 91 patients 
(42.7%) had succumbed and 51 of them died of lung cancer. 
Advanced pathological stage, nodal metastasis, EFGR mutation, 
and MET mutation were prognostic factors of overall survival. 
Multivariate analysis revealed that advanced pathological stage, 
nodal metastasis, EFGR mutation, and MET mutation were inde-
pendent prognostic parameters. Mutated EGFR was associated 
with better overall survival (hazard ratio, 0.49; 95% CI: 0.27–0.91; 
p = 0.024), whereas mutated MET was related to poorer overall 
survival (hazard ratio, 2.98; 95% CI: 1.03–8.67; p = 0.045).
Excluding 17 patients underwent palliative surgery, 71 
patients (58.1%) were free of recurrence, and 51 (41.9%) had 
tumor relapse. The median duration of tumor relapse was 29.9 
months. Nodal metastasis was the only prognostic factor pre-
dicting tumor relapse. None of molecular alteration was asso-
ciated with tumor recurrence (Fig. 3 and Table 3).
DISCUSSION
Driver mutations in the RTK axis have been proven to be 
useful predictive biomarkers for targeted therapies that facilitate 
personalized medicine. Lung cancers demonstrate high rates of 
somatic mutation, and the list of actionable genetic alterations 
is growing during the past decade. Our study comprehensively 
investigated the frequencies and clinicopathological correla-
tions of known actionable driver events in RTK/RAS/PI3K 
pathway in a Chinese cohort of lung adenocarcinoma. The 
results indicated that two thirds of the lung adenocarcinomas 
(70%, 104 of 149) carried actionable genetic events. EGFR and 
KRAS are the two most frequently mutated genes that occur in 
43.0% and 11.4% of the tumors, respectively. Compared with 
ever-smokers, never-smokers had a higher EGFR mutation rate 
(59% in never-smoker versus 25% in ever-smoker) and lower 
KRAS mutation rate (6.4% in never smoker versus 21.4% in 
ever smoker). Notably, male and female never-smokers had a 
similar EGFR mutation rate (62% and 57%, respectively), indi-
cating gender is not a selection criteria for EGFR testing. In 
contrast, male patients had higher proportions of KRAS muta-
tions compared with female irrespective of smoking status.
No significant difference was observed between patient 
smoking history and gender in ALK, BRAF, and MET muta-
tion status probably because of the limited sample size in this 
study. In addition, overall higher proportion of never-smokers 
tended to carry driver mutation-defined tumors than smok-
ers though the difference did not reach statistical significance 
(77% versus 63%, p = 0.07). Individual mutations in RTK/
RAS/PI3K pathway show specific demographic tendency, and 
therefore, similar studies could yield differential mutation spec-
trums. Our cohort composed of never-smoker predominated TA
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East Asian (Never-smoker to Ever-smoker ratio = 1.39). When 
comparing with other East Asian cohorts, the mutation pattern 
was more or less similar if stratified by smoking status,14,26 
However, the EGFR and KRAS shown reversed mutation rate 
in Caucasian population compare with our results regardless 
of never-smoker to ever-smoker ratio,22,30 indicating ethnicity 
play important role in this discrepancy.
Driver mutation arises early during most tumor devel-
opment, and single hit is enough to activate RTK path-
way. Hence, they are usually mutually exclusive with each 
other.31,32 However, tumors with double mutations are some-
times reported. Two lung adenocarcinomas in this cohort har-
bor co-mutations. One carries ALK translocations and NRAS 
mutation and the other harbors BRAF and PIK3CA muta-
tions. Previous studies found PIK3CA mutations have a high 
chance to overlap with other mutations. Patients with double 
mutations show inferior survival.33,34 Furthermore, overlap-
ping PIK3CA/EGFR mutations contribute to resistance of 
EGFR TKIs. ALK translocations are also reported to coex-
ist with EGFR or KRAS mutation. Patients with concomitant 
EGFR and ALK aberrations are responsive toward EGFR 
TKIs. The differential responses to targeting agents in tumors 
with co-mutations underscore the importance of comprehen-
sive molecular profiling for lung adenocarcinoma.35–37
Prognostic significances of individual driver mutations 
have been investigated in many studies and summarized in dif-
ferent meta-analyses.38 We demonstrated that mutated MET 
and wild-type EGFR were two independent prognostic factors 
of overall survival, but they did not predict the tumor recur-
rence. As majority of patients had disease beyond stage I, they 
are eligible for adjuvant systemic therapy according to current 
guidelines. The nature of systemic therapy could greatly influ-
ence overall survival. Although the data of adjuvant therapy 
was incomplete in our cohort, it is likely that advancement in 
EGFR-targeted therapy may explain that patients with EGFR 
mutation have a better overall survival than patients with MET 
mutation but not relapse-free survival.
Our study highlights potential therapeutic significance 
of MET DNA alteration in lung adenocarcinoma. MET 
DNA alterations define a subset of patients with older age 
and poorer prognosis that potentially might be beneficial by 
anti-MET targeting agents. Despite the positive MET pro-
tein expression that can be seen in 65% of lung adenocarci-
noma, only 10% of these cases harbor MET DNA alterations 
that drive the overexpression of MET protein. Upregulation 
of MET protein in 90% of the MET IHC-positive tumors 
might be secondary events that promote tumor progres-
sion but not the key driver of individual tumors. Although 
TABLE 3.  Univariate and Multivariate Cox Regression Analysis for Overall and Relapse-free Survival in Patients with  
Lung Adenocarcinomas
Parameter
Univariate Analysis Multivariate Analysis
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Overall survival
  Age (yr) 1.00 0.98–1.03 0.883
  Male 1.51 0.86–2.65 0.153
  Ever smoking 1.67 0.95–2.95 0.077
  Advanced pathological stage 4.60 2.49–8.48 <0.001b 4.85 2.55–9.22 <0.001b
  Nodal metastasisa 2.60 1.48–4.59 0.001b
  Tumor size (cm) 0.93 0.77–1.13 0.460
  EGFR mutation 0.48 0.26–0.87 0.015c 0.49 0.27–0.91 0.024c
  KRAS mutation 1.70 0.77–3.78 0.193
  ALK translocation 1.46 0.62–3.42 0.389
  MET mutation 2.93 1.05–8.21 0.041c 2.98 1.03–8.67 0.045c
Relapse free survival
  Age (yr) 1.00 0.97–1.02 0.878
  Male 1.25 0.71–2.20 0.444
  Ever smoking 1.17 0.66–2.07 0.589
  Advanced pathological stage 1.06 0.25–4.46 0.932
  Nodal metastasis 2.46 1.40–4.33 0.002b 2.46 1.40–4.33 0.002c
  Tumor size (cm) 0.88 0.73–1.07 0.201
  EGFR mutation 0.82 0.47–1.45 0.498
  KRAS mutation 1.95 0.87–4.38 0.105
  ALK translocation 1.47 0.62–3.48 0.387
  MET mutation 1.51 0.36–6.28 0.573
aNodal metastasis was excluded for multivariate analysis to avoid multicollinearity with advanced pathological stage.
bP < 0.05.
cP < 0.01.
CI, confidence interval.
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a recent study pooled over 5000 NSCLC cases for meta-
analysis found MET protein overexpression predict poor 
prognosis in lung adenocarcinoma,39 these tumors might not 
be response to anti-MET targeting agents. In fact, phase III 
clinical trials using MET protein expression as biomarker 
for patient selection failed to show improvement in overall 
and progressive-free survival (The MetLung and the MET 
Inhibitor Tivantinib (ARQ197) Plus Erlotinib vs Erlotinib 
Plus Placebo in NSCLC [MARQUEE] study). Our findings 
underscore the significance of proper selection of predictive 
biomarkers, which is essential for patient management in the 
new era of personalize medicine. The high negative predic-
tive value of MET protein expression level for the presence 
of MET DNA alterations is intriguing. MET IHC is conve-
niently available in routine diagnostic laboratory that allows 
for a fast screening for patients with lung adenocarcinoma to 
join proper molecular test.
Lack of TTF-1 expression in lung adenocarcinoma has 
been associated with higher KRAS and lower EGFR muta-
tion rate in previous studies.40,41 It was proposed that lung 
adenocarcinoma could be classified into TRU subtype and 
non-TRU subtypes principally according to TTF-1 expres-
sion.42 TRU cell lines are more sensitive to EGFR TKIs, 
whereas non-TRU cell lines are more sensitive toward cis-
platin regardless of KRAS status. In this study, a high nega-
tive predictive value of TTF-1 for the presence of EGFR and 
MET mutation suggested a potential role for TTF-1 as a sur-
rogate marker.
In conclusion, actionable driver events can be detected 
in two thirds of lung adenocarcinoma from Chinese ethnicity. 
MET DNA alterations define a subset of patients with aggres-
sive diseases that might potentially benefit from anti-MET tar-
geted therapy. High negative predictive values of TTF-1 and 
MET expression suggest potential roles as surrogate markers 
for EGFR and/or MET mutations.
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